The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met

The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06959589 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 50 participants, started 2025-05-22 and due to reach its primary completion in 2027-05-31. Interventions recorded: IBI351, cetuximab β combined with FOLFIRI. Conditions listed: Colorectal Cancer Metastatic; KRAS G12C Mutation. Primary outcome: ORR. Colorectal eligibility wording from the registry: "The patient must have histologically and/or cytologically confirmed metastatic colorectal cancer (stage IV) 3". Sites: China. No results are recorded here; the registry entry is the source.